Research Paper Volume 12, Issue 13 pp 13365—13387
TCF7L2 rs290487 C allele aberrantly enhances hepatic gluconeogenesis through allele-specific changes in transcription and chromatin binding
- 1 Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 2 Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 3 Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
- 4 State Key Lab for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- 5 Department of Endocrinology and Metabolism, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Received: February 8, 2020 Accepted: May 25, 2020 Published: July 10, 2020https://doi.org/10.18632/aging.103442
How to Cite
Copyright © 2020 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In this study, we investigated the mechanisms underlying the altered hepatic glucose metabolism and enhanced diabetes risk in individuals with the TCF7L2 rs290487 C allele. Analysis of 195 cirrhotic patients revealed a higher insulin resistance index and incidence of hepatogenous diabetes in patients with the rs290487 C/C genotype compared to those with the C/T or T/T genotype. The in vitro experiments using targeted mutant PLC-PRF-5 cell line showed that cells with the rs290487 C/C genotype (C/C cells) had higher glucose production, lower glucose uptake, and lower TCF7L2 mRNA and protein levels than those with the C/T genotype (C/T cells). Integrated multi-omics analysis of ChIP-seq, ATAC-seq, RNA-seq, and metabolomics data showed genome-wide alterations in the DNA binding affinity of TCF7L2 in the C/C cells, including gain (e.g., PFKP and PPARGC1A) and loss (e.g., PGK1 and PGM1) of binding sites in several glucose metabolism-related genes. These allele-specific changes in transcriptional regulation lead to increased expression of gluconeogenesis-related genes (PCK1, G6PC and PPARGC1A) and their downstream metabolites (oxaloacetate and β-D-fructose 2,6-bisphosphate). These findings demonstrate that the TCF7L2 rs290487 C allele enhances gluconeogenesis through allele-specific changes in transcription and chromatin binding.
ATAC-seq: Assay for transposase-accessible chromatin using sequencing; BMI: Body mass index; ChIP-seq: chromatin immunoprecipitation followed by sequencing; DEG: Differentially expressed gene; F2,6BP: β-D-Fructose 2,6-bisphosphate; HD: Hepatogenous diabetes; HOMA-IR: Homeostatic model assessment for insulin resistance; PCA: Principal component analysis; PLS-DA: Partial least squares discrimination analysis; RNA-seq: Ribonucleic acid sequencing; SNP: Single nucleotide polymorphism; TCF7L2: Transcription factor-7-like 2.